Related Experiment Video
Updated: May 30, 2026

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
Published on: March 7, 2025
Zebrafish as a potential model organism for drug test against hepatitis C virus
Cun-Bao Ding1, Jing-Pu Zhang, Ye Zhao
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
Screening and evaluating anti- hepatitis C virus (HCV) drugs in vivo is difficult worldwide, mainly because of the lack of suitable small animal models. We investigate whether zebrafish could be a model organism for HCV replication. To achieve NS5B-dependent replication an HCV sub-replicon was designed and created with two vectors, one with HCV ns5b and fluorescent rfp genes, and the other containing HCV's 5'UTR, core, 3'UTR and fluorescent gfp genes. The vectors containing sub-replicons were co-injected into zebrafish zygotes. The sub-replicon amplified in liver showing a significant expression of HCV core RNA and protein. The sub-replicon amplification caused no abnormality in development and growth of zebrafish larvae, but induced gene expression change similar to that in human hepatocytes. As the amplified core fluorescence in live zebrafish was detectable microscopically, it rendered us an advantage to select those with replicating sub-replicon for drug experiments. Ribavirin and oxymatrine, two known anti-HCV drugs, inhibited sub-replicon amplification in this model showing reduced levels of HCV core RNA and protein. Technically, this method had a good reproducibility and is easy to operate. Thus, zebrafish might be a model organism to host HCV, and this zebrafish/HCV (sub-replicon) system could be an animal model for anti-HCV drug screening and evaluation.
Insights
Zebrafish can host hepatitis C virus (HCV) replication, offering a novel small animal model for drug screening. This system enables efficient evaluation of anti-HCV compounds like ribavirin and oxymatrine.
Area of Science:
- Virology
- Genetics
- Animal Models
Background:
- Screening anti-hepatitis C virus (HCV) drugs in vivo is challenging due to limited small animal models.
- Zebrafish are being investigated as a potential model organism for HCV replication.
Purpose of the Study:
- To investigate the potential of zebrafish as a model for HCV replication.
- To develop a zebrafish-based system for screening and evaluating anti-HCV drugs.
Main Methods:
- An HCV sub-replicon was engineered into two vectors for co-injection into zebrafish zygotes.
- NS5B-dependent replication was achieved, and gene expression changes were analyzed in zebrafish larvae.
- Fluorescence detection of amplified HCV core was used to select larvae for drug experiments.
Main Results:
- The HCV sub-replicon amplified in zebrafish liver, showing significant expression of HCV core RNA and protein without causing developmental abnormalities.
- Gene expression changes in zebrafish larvae mimicked those in human hepatocytes.
- Two known anti-HCV drugs, ribavirin and oxymatrine, successfully inhibited sub-replicon amplification in the zebrafish model.
Conclusions:
- Zebrafish can support HCV replication and serve as a viable small animal model.
- The developed zebrafish/HCV sub-replicon system offers a reproducible and accessible platform for anti-HCV drug screening and evaluation.

